Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization


China NMPA approval based on...

Related Keywords

Japan ,Macau ,Laos ,Philippines ,Hong Kong ,Cambodia ,Taiwan ,New Zealand ,Vietnam ,Republic Of ,Indonesia ,Australia ,Thailand ,United States ,Singapore ,China ,Malaysia ,Chinese ,Harald Reinhart ,Matt Ronsheim ,Acinetobacter Baumannii ,Centers For Disease ,Head Of Global Development ,Zai Lab Limited ,Zai Lab ,Securities Exchange ,Innoviva Inc ,Drug Administration ,Zai Lab Forward ,Exchange Commission ,Jolla Pharmaceutical Company ,Entasis Therapeutics Inc ,Zai Lab New Drug Application ,World Health Organization ,China National Medical Products Administration ,Innoviva Specialty Therapeutics ,National Medical Products Administration ,New Drug Application ,Global Development ,Infectious Diseases ,Innoviva Specialty ,Greater China ,Disease Control ,Acinetobacter Baumannii Infections ,Full Prescribing Information ,Private Securities Litigation Reform Act ,Specialty Therapeutics ,Specialty Therapeutic ,Securities Exchange Act ,Financial Condition ,Annual Report ,Quarterly Reports ,Risk Factors ,Clinical Presentation ,Molecular Bacterial Pathogenesis Volume ,Antimicrobial Resistance ,Rev Drug ,Antibiotic Resistance ,Patient Safety ,China Diagnosis ,Treatment Guideline ,